Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Cancer Manag Res · 2010 · PMC3004568 · PMID 21188096

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

There was no difference in the overall response rate between the 9 or 18 μg/kg/day cohorts; however, a subset analysis of patients with stage IIB disease or higher, showed a trend towards higher response ( P = 0.07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.